

# Keratitis - Pipeline Review, H1 2020

<https://marketpublishers.com/r/K4D71D94641EN.html>

Date: April 2020

Pages: 84

Price: US\$ 2,000.00 (Single User License)

ID: K4D71D94641EN

## Abstracts

Keratitis - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H1 2020, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 12 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules,

respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Keratitis - Overview
- Keratitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Keratitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Keratitis - Companies Involved in Therapeutics Development
- Alfasigma SpA
- AmebaGone Inc
- Cumulus Pharmaceutical LLC
- Dobecure SL
- Editas Medicine Inc
- Eleusis Ltd
- EyeGate Pharmaceuticals Inc
- Fox Chase Chemical Diversity Center Inc
- iVeena Delivery Systems Inc
- MimeTech Srl
- NanoViricides Inc
- RegeneRx Biopharmaceuticals Inc
- Riptide Bioscience Inc
- Shulov Innovative Science Ltd
- SIFI SpA
- Sinsa Labs Inc
- TGV-Inhalonix Inc
- Veloce BioPharma LLC
- Viraze
- Keratitis - Drug Profiles
- acyclovir sodium - Drug Profile
- Product Description

Mechanism Of Action  
R&D Progress  
amphotericin B - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
B-2088 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Biologics for Bacterial Keratitis - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ELE-02 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ethamsylate - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Gene Therapy for Herpetic Keratitis - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
IBN-1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
imbetasin acetate - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
IVMED-90 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
JDE-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-55933 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIM-45 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polihexanide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-557 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

targocil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udonitrectag - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

**VBP-245 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Z-9445 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**ZEP-3 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**ZEP-4 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Keratitis - Dormant Projects**

Keratitis - Discontinued Products

Keratitis - Product Development Milestones

Featured News &amp; Press Releases

Apr 02, 2020: New provide pandemic response program to clients for T?4 in Corneal Wound Healing and Regeneration

Oct 23, 2019: Eleusis presents new research on the anti-inflammatory potential of serotonin 2A receptor agonists at the 2019 International Society for Research on Psychedelics

Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis

Oct 13, 2017: ODAK Project:Phase III Clinical Trial is ready to start in Italy

Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease

Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday

Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials

Sep 30, 2015: RegeneRx Receives \$500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S.

Neurotrophic Keratopathy Clinical Trial with RGN-259  
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops  
for the Treatment of Neurotrophic Keratopathy

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Keratitis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Keratitis - Pipeline by Alfasigma SpA, H1 2020  
Keratitis - Pipeline by AmebaGone Inc, H1 2020  
Keratitis - Pipeline by Cumulus Pharmaceutical LLC, H1 2020  
Keratitis - Pipeline by Dobecure SL, H1 2020  
Keratitis - Pipeline by Editas Medicine Inc, H1 2020  
Keratitis - Pipeline by Eleusis Ltd, H1 2020  
Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H1 2020  
Keratitis - Pipeline by Fox Chase Chemical Diversity Center Inc, H1 2020  
Keratitis - Pipeline by iVeena Delivery Systems Inc, H1 2020  
Keratitis - Pipeline by MimeTech Srl, H1 2020  
Keratitis - Pipeline by NanoViricides Inc, H1 2020  
Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2020  
Keratitis - Pipeline by Riptide Bioscience Inc, H1 2020  
Keratitis - Pipeline by Shulov Innovative Science Ltd, H1 2020  
Keratitis - Pipeline by SIFI SpA, H1 2020  
Keratitis - Pipeline by Sinsa Labs Inc, H1 2020  
Keratitis - Pipeline by TGV-Inhalonix Inc, H1 2020  
Keratitis - Pipeline by Veloce BioPharma LLC, H1 2020  
Keratitis - Pipeline by Viraze, H1 2020  
Keratitis - Dormant Projects, H1 2020  
Keratitis - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Keratitis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Alfasigma SpA  
AmebaGone Inc  
Cumulus Pharmaceutical LLC  
Dobecure SL  
Editas Medicine Inc  
Eleusis Ltd  
EyeGate Pharmaceuticals Inc  
Fox Chase Chemical Diversity Center Inc  
iVeena Delivery Systems Inc  
MimeTech Srl  
NanoViricides Inc  
RegeneRx Biopharmaceuticals Inc  
Riptide Bioscience Inc  
Shulov Innovative Science Ltd  
SIFI SpA  
Sinsa Labs Inc  
TGV-Inhalonix Inc  
Veloce BioPharma LLC  
Viraze

## I would like to order

Product name: Keratitis - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/K4D71D94641EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K4D71D94641EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970